Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.94%
#3 Cysic Cysic +15.83%
#4 Fabric Protocol Fabric Protocol +10.45%
#5 Perle Perle +8.39%
#6 Bedrock Bedrock +7.48%
#7 Cap Cap +4.08%
#8 BOOK OF MEME BOOK OF MEME +3.93%
#9 Dual Dual +3.60%
#10 stake.link stake.link +3.56%
Coin of the day
EXOD EXOD
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Anatara Lifesciences Ltd Anatara Lifesciences Ltd

Anatara Lifesciences Ltd

ANR
Kedudukan dalam Saham #37961
Anatara Lifesciences Ltd is an Australian enterprise focused on researching,... Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression. In the animal health sector, Anatara provides Detach for treating diarrhea in piglets, BONIFF as an enhanced dry feed formulation for weaned piglets, and ANR-pf, a unique additive for poultry drinking water. This company was founded in 2010 and is headquartered in Carlton, Australia.
Harga Saham
$0.00634756
Disegerakkan terakhir: 2026-08-14
Modal Pasaran
$1.32M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
39.40%
Negara
AU
Perdagangan Anatara Lifesciences Ltd (ANR)

Kategori

Healthcare
Pendapatan untuk Anatara Lifesciences Ltd (ANR)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Anatara Lifesciences Ltd, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Anatara Lifesciences Ltd dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE